Abstract
Because of the reported activity of the lipid-soluble nitrosoureas in non-small cell carcinoma of the lung, a phase II trial of chlorozotocin in this disease was undertaken. Thirty-five patients were enlisted in the study between March 1977 and March 1978. Two PRs were noted in the 30 (7%) evaluable patients. At 95% confidence limits, the predicted true response rate is 2%-18%. The authors conclude that chlorozotocin, when given in the present dose and schedule, is only a marginally effective agent in the treatment of non-small cell carcinoma of the lung, and that it offers no therapeutic advantage over the nitrosoureas currently used in the treatment of this disease.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 549-550 |
| Number of pages | 2 |
| Journal | Cancer Treatment Reports |
| Volume | 63 |
| Issue number | 4 |
| State | Published - Dec 1 1979 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
